Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.

AT&T shares have fallen 17% in 2026, hitting new lows this week, amid concerns about SpaceX expanding its Starlink mobile service. The telecom stock's decline comes despite its stable business and typically reliable long-term growth prospects. Investors worry increased competition from Starlink could further limit AT&T's growth opportunities. However, some analysts believe the market may be overreacting to the threat. The company maintains strong fundamentals with steady cash flow supporting its dividend payments. AT&T's current challenges have pushed its dividend yield higher, potentially making it attractive for income-focused investors willing to overlook near-term competitive pressures. Sanofi and Vici Properties also recently hit 52-week lows whilst offering high dividend yields above 5%, presenting potential opportunities for bargain hunters seeking quality dividend stocks at reduced valuations.

Deutsche Bank has cut its price target on Sanofi to €95 from €100 whilst maintaining a Buy rating on the shares. The pharmaceutical company reported strong fiscal Q1 2026 results, with sales growing 13.6% at constant exchange rates and business earnings per share reaching €1.88. Sanofi's newly launched pharmaceuticals drove performance, with sales rising 49.6% to €1.2 billion, led by Ayvakit, ALTUVIIIO and Sarclisa. Dupixent sales grew 30.8% to €4.2 billion, whilst vaccine sales increased 2.1% to €1.3 billion. Research and development expenses rose 1.5% to €1.7 billion, whilst selling and general expenses climbed 11.6% to €2.3 billion, primarily reflecting recent acquisitions. Sanofi operates through three segments: Pharmaceuticals, Consumer Healthcare and Vaccines.